tranexamic acid

(redirected from Lysteda)
Also found in: Encyclopedia.

tranexamic acid

 [tran″ek-sam´ik]
an agent that combats fibrinolysis by competitively inhibiting activation of plasminogen; used in prophylaxis and treatment of hemorrhage associated with excessive fibrinolysis, such as that following oral surgery in patients with hemophilia; administered orally or intravenously.

tran·ex·am·ic ac·id

(tran'eks-am'ik as'id),
A competitive inhibitor of plasminogen activation and of plasmin; used in hemophilia to reduce or prevent hemorrhage.

tranexamic acid

/tran·ex·am·ic ac·id/ (tran″ek-sam´ik) an antifibrinolytic that competitively inhibits activation of plasminogen; used as a hemostatic in the prophylaxis and treatment of severe hemorrhage associated with excessive fibrinolysis.

tranexamic acid

[tran′ek-sam′ik]
an agent that combats fibrinolysis by competitively inhibiting activation of plasminogen. It is used in prophylaxis and treatment of hemorrhage associated with excessive fibrinolysis, such as that after oral surgery in patients with hemophilia. It is administered orally or intravenously.

tranexamic acid

A drug that interferes with the dissolution of blood clot (fibrinolysis) and can be used to prevent bleeding during minor operations such as tooth extraction in people with HAEMOPHILIA. A brand name is Cyklokapron.

tranexamic acid

an antifibrinolytic agent, used orally or intravenously to control hemorrhage. Called also Vasolamin.
References in periodicals archive ?
The company added the tranexamic acid tablets are the generic equivalent to Ferring Pharmaceuticals' Lysteda.
Effective immediately, Watson plans to begin shipping the generic Lysteda tablets, which is indicated for the treatment of cyclic heavy menstrual bleeding.
According to IMS Health data, Lysteda had total US sales of about USD25m for the 12 months ending 30 November 2012.
Lysteda is a nonhormonal lysine analog that acts as a competitive plasmin inhibitor; it is not a contraceptive.
The most common adverse events in the Lysteda groups were upper respiratory infection (7%), musculoskeletal pain (5%), and myalgia (5%) in one study, and headache (11%), nausea (10%), and menstrual discomfort (8%) in the other study.
and Ferring Pharmaceuticals, which acquired global marketing rights to Lysteda last May.
According to the FDA, Lysteda (Xanodyne Pharmaceuticals) is the first non-hormonal product approved for heavy menstrual bleeding, which affects about 3 million women a year.
The agency cautioned against using Lysteda in conjunction with oral hormonal contraceptives due to an increased risk of blood clots, stroke, or MI.
According to the FDA, Lysteda, made by Xanodyne Pharmaceuticals of Newport, Ky.
According to the FDA, Lysteda, made by Xanodyne Pharmaceuticals, is the first nonhormonal product approved for heavy menstrual bleeding.
The agency cautioned against using Lysteda in conjunction with oral hormonal contraceptives because of an increased risk of blood clots, stroke, or myocardial infarction.